SAGITTA iudicium, Genentech, NSCLC, pralsetinib
Pralsetinib approbatur a FDA pro cancro cellulae non parvae cum fusions gene ret
Augusti 2023: Pralsetinib (Gavreto, Genentech, Inc.) approbatio ordinaria data est a Administration Cibus et medicamentis ad aegros adultos cum metastatica RET fusione-positiva non parva cellula pulmonis cancri (NSCLC), secundum determinatum FDA.
CD20, Columvi, DLBCL, Genentech
Glofitamab-gxbm approbatur a FDA pro delectis relapsis vel refractoriis magnas lymphomas B-cell.
Iulii 2023: Cibus et Administration medicamentis approbationem ad glofitamab-gxbm acceleratam dederunt (Columvi, Genentech, Inc.) pro relapso vel refractorio diffusione magna lymphoma B-cell, non aliter determinata (DLBCL, NOS) vel magna B-cell iy.
Genentech, Lunsumio, mosunetuzumab-axgb, durum folliculorum lymphoma
Mosunetuzumab-axgb conceditur approbatione accelerato pro lymphoma folliculari relapso vel refractorio.
Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), bispecificus CD20-directus CD3 T-cellens aggressor pro aegris adultis relapso vel refractorio lymphoma folliculari (FL) sequentes duos vel plures orbes systemicas therapiae, recc.
alveolaris mollis pars sarcoma, Atezolizumab, systematis nervosi centralis, Genentech, Tecentriq
Atezolizumab approbatur a FDA ad textus mollis alveolaris sarcoma
Dec 2022: Atezolizumab (Tecentriq, Genentech, Inc.) Cibus et medicamentis Administration (FDA) probatus est aegris adultis et pediatricibus cum nonsectabili vel metastatico alveolaris partis mollis sarcomae quae sunt 2 anni a.
Burkitt lymphoma, Burkitt-sicut lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab plus chemotherapy probatur ex FDA ad indicia cancri pediatrici
Martii 2022 : Cibus et medicamentum administrationis rituximab (Rituxan, Genentech, Inc.) approbavit in coniunctione cum chemotherapy pro CD20-positiva diffusa lymphoma magna B-cella (DLBCL), Burkitt lymphoma (BL), Burkitt-lymphoma simile.
Atezolizumab, Genentech, NSCLC, Tecentriq, Ventana Systems Medicum, VENTANA PD-L1
Atezolizumab approbatur a FDA ad adjuvandum curationem carcinomatis cellulae non parvae
Nov 2021: Cibus et medicamentum Administrationis atezolizumab (Tecentriq, Genentech, Inc.) approbavit curationem patientibus scaena II ad IIIA non parvam cellulam pulmonis cancri (NSCLC) cuius tumores expressio PD-L1 continent o.